AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02353468
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02353468
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02353468
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT03380780
Drug: Emicizumab
RxNorm normalized name: Emicizumab
DrugBank: Emicizumab (DB13923)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive a single 1 milligram per kilogram of body weight (mg/kg) subcutaneous dose of emicizumab on Day 1.
Trial: NCT00535379
Drug: Sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
Trial: NCT01647542
Drug: TAK-875
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 tablets
Trial: NCT01374802
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg tablet for oral administration
Trial: NCT01374802
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablet for oral administration
Trial: NCT04678739
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remdesivir 100 IV Infusion as a lyophilized powder
Trial: NCT04678739
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Actemra IV Infusion
Trial: NCT01374802
Drug: BI 201335
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00992342
Drug: PF-03893787
RxNorm normalized name: PF-03893787
DrugBank: Adriforant (DB15027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, 5 mg, QD for 14 days
Trial: NCT00992342
Drug: PF-03893787
RxNorm normalized name: PF-03893787
DrugBank: Adriforant (DB15027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, 15 mg, QD for 14 days
Trial: NCT01267253
Drug: Brivanib Alaninate
RxNorm normalized name: Brivanib alaninate
DrugBank: Brivanib alaninate (DB11865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00992342
Drug: PF-03893787
RxNorm normalized name: PF-03893787
DrugBank: Adriforant (DB15027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution, 50 mg, QD for 14 days
Trial: NCT02214953
Drug: BI 11634 ER formulation A
RxNorm normalized name: Combretastatin A-1 bis(phosphate)
DrugBank: OXI-4503 (DB05143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214953
Drug: BI 11634 ER formulation B
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214953
Drug: BI 11634 ER formulation M
RxNorm normalized name: potassium chloride
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02214953
Drug: BI 11634 ER formulation C
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214953
Drug: BI 11634 IR tablet
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02638103
Drug: Fremanezumab
RxNorm normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fremanezumab will be administered as per the dose and schedule specified in the respective arms.
Trial: NCT02842437
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
Trial: NCT02768558
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrently with radiation therapy, 50 mg/m2, IV, on days 1, 8, 29, and 36, to begin with day 1 of radiation therapy.
Trial: NCT02768558
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concurrently with radiation, 40 mg/m2, IV, on days 1-5 and 29-33, to begin with day 1 of radiation therapy.
Trial: NCT02768558
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Beginning 4-12 weeks after chemoradiation, 240 mg, IV, every 2 weeks for 16 weeks, then 480 mg, IV, for 36 weeks.
Trial: NCT00406458
Drug: SB-509
RxNorm normalized name: SB-509
DrugBank: SB-509 (DB05579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg dose
Trial: NCT02294474
Drug: Humalog
RxNorm normalized name: HumaLOG
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
Trial: NCT02294474
Drug: insulin glargine HOE901
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Trial: NCT02008968
Drug: allopurinol 300 mg./day
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02008968
Drug: Normouricemic
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00115518
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
Trial: NCT04268537
Drug: PD-1 blocking antibody+standard treatment
RxNorm normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, PD-1 blocking antibody 200mg iv, one time. Standard treatment is according to the protocol of treatment of 2019-nCoV infection
Trial: NCT02265666
Drug: BIIL 284 BS Tablet FF
RxNorm normalized name: BS-001
DrugBank: BS-001 (DB17415)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00288951
Drug: Travoprost 0.004% with and without BAK
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00514046
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily continuously (28 day cycles)
Trial: NCT01800708
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03101124
Drug: Tranexamic Acid 25 mg/ml for wound surface moistening
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
Trial: NCT03101124
Drug: Tranexamic Acid 5 mg/ml as bolus in wound cavity
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
Trial: NCT03101124
Drug: Tranexamic Acid Injectable Solution
RxNorm normalized name: tranexamic acid Injection
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
Trial: NCT02021539
Drug: Tocolytic treatment for 2 hours
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
Trial: NCT03714568
Drug: TQ-A3326
RxNorm normalized name: TQS-168
DrugBank: TQS-168 (DB18108)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses）
Trial: NCT01663038
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel and Aspirin separate combination, single dose
Trial: NCT01663038
Drug: Fixed dose combination of clopidogrel/Aspirin
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed dose combination of clopidogrel/aspirin
Trial: NCT01663038
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00095823
Drug: Antidepressant + Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
Trial: NCT01181245
Drug: FG-3019
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
Trial: NCT01234766
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 90mg/m2, IV - Days 1 and 2 of every cycle
Trial: NCT01234766
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
Trial: NCT04330690
Drug: Artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care
Trial: NCT04330690
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg enterally daily for 14 days plus standard of care
Trial: NCT04330690
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg IV given one time, over 2 hours plus standard of care
Trial: NCT04330690
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10
Trial: NCT04330690
Drug: LSALT Peptide
RxNorm normalized name: LSALT Peptide
DrugBank: LSALT Peptide (DB16472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg , 2 hour IV infusion once daily for up to 14 consecutive days
Trial: NCT02177253
Drug: Ipratropium bromide / Salbutamol
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177253
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02177253
Drug: COMBIVENT Inhalation Aerosol
RxNorm normalized name: Combivent Inhalant Product
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01212406
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
Trial: NCT06250543
Drug: Lidocain
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 minutes before the procedure the bladder was instilled with 40 ml of 1% lidocaine solution using a 16Fr urethral Foley catheter
Trial: NCT01641653
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-2.5 mg
Trial: NCT01843790
Drug: GCS-100
RxNorm normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
Trial: NCT04560751
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules will be administered orally, once daily (for patients \<60kg, lenvatinib 8mg po; for patients ≥60kg, lenvatinib 12mg po)
Trial: NCT00518713
Drug: Clobazam Low Dose
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg/day; tablets; orally; for 15-18 weeks
Trial: NCT00518713
Drug: Clobazam Medium Dose
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg/day; tablets; orally; for 15-18 weeks
Trial: NCT00518713
Drug: Clobazam High Dose
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg/day; tablets; orally; for 15-18 weeks
Trial: NCT00279253
Drug: clonidine (drug) intravenously
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00194324
Drug: Miconazole nitrate
RxNorm normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00997256
Drug: film-coated sugar-pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 2 tablets / day over 3 days
Trial: NCT01118559
Drug: YM150
RxNorm normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01081847
Drug: Peptides (N,R&C) formulated in Montanide ISA 720
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ug
Trial: NCT01081847
Drug: Peptides (N,R&C) formulated in Montanide ISA 51
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ug
Trial: NCT01081847
Drug: Peptides (N,R&C) formulated in Montanide ISA 720
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ug
Trial: NCT01081847
Drug: Peptides (N,R&C) formulated in Montanide ISA 51
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ug
Trial: NCT02594449
Drug: Benzalkonium Chloride Solution
RxNorm normalized name: Benzalkonium Chloride Solution
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To compare pharmacodynamics among the different concentrations of BCS and NS
Trial: NCT02039076
Drug: avatrombopag
RxNorm normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00174837
Drug: Tirapazamine
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in combination with cisplatin and concomitant radiation
Trial: NCT00174837
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: with concomitant radiation
Trial: NCT00589303
Drug: FDA approved rate and rhythm control drugs
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.~Rate Control:~Beta-Blocker:~* metoprolol~* atenolol~* carvedilol~Calcium Channel Blocker:~* verapamil~* diltiazem~Rhythm Control:~* procainamide~* quinidine~* disopyramide~* propafenone~* flecainide~* sotalol~* dofetilide~* amiodarone
Trial: NCT00399243
Drug: Sumatriptan 4mg Statdose injection
RxNorm normalized name: sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
Trial: NCT04184453
Drug: Deferiprone treated
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone (25 mg/kg/day) was given to the enrolled patients.
Trial: NCT00295815
Drug: enzastaurin
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
Trial: NCT00295815
Drug: lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100-130 mg/m2, oral once, every 6 weeks until PD
Trial: NCT04219995
Drug: methylprednisolone sodium succinate
RxNorm normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate will be re-constituted in simple syrup in a concentration of 80mg/mL and will be administered orally at 20mg/kg (max 1000mg) for days 1, 2, and 3 of the intervention phase of the study.
Trial: NCT04149938
Drug: Lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04149938
Drug: Lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03740243
Drug: Buprenorphine/naloxone
RxNorm normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine/naloxone tablet or film
Trial: NCT03740243
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine tablet
Trial: NCT01107899
Drug: clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: taken orally, day one, single dose
Trial: NCT01107899
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: taken orally, day one, single dose
Trial: NCT00223301
Drug: Mycophenolate Mofetil (cellcept)
RxNorm normalized name: MYCOPHENOLATE MOFETIL (CELLCEPT) 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01384812
Drug: isoton sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous injection for 25 min
Trial: NCT03908567
Drug: Intranasal Drug
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of solution with betahistine dihydrochloride; Dosing 3 times a day
Trial: NCT03908567
Drug: Oral Tablet
RxNorm normalized name: Oral Tablet
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dosing with tablets 3 times a day
Trial: NCT02092532
Drug: Rescue Intravitreal Aflibercept Injection
RxNorm normalized name: aflibercept Injection
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
Trial: NCT02605746
Drug: ceritinib 750mg
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00398281
Drug: dutasteride
RxNorm normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00519636
Drug: FFNS
RxNorm normalized name: Fluticasone Furoate Nasal Spray
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: fluticasone furoate nasal spray
Trial: NCT00979953
Drug: ADL5859
RxNorm normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00240214
Drug: sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, dosage is determined by trough level
Trial: NCT01207050
Drug: Ramelteon
RxNorm normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8mg capsule taken within one half hour of bedtime each night over the three night study period.